12 May 2017
Tilray has partnered with Alef Biotechnology SpA to import and distribute medical cannabis products in Chile, where law permits patients to access medical cannabis under the supervision of a recommending physician. Tilray products in Chile will be distributed only to patients with prescriptions under a series of safeguards to promote safe and responsible use. Alef is licensed by the Chilean government to commercially produce medical cannabis. Tilray announced its partnership with Alef in February 2017.
“Alef Biotechnology is committed to improving the quality of life of patients in need,” said Roberto Roizman, President of the Alef Biotechnology Board. “By importing Tilray’s medical cannabis products to Chile we intend to ease the suffering of those in need by offering pure, precise and predictable medical cannabis products.”
Tilray currently supplies pharmaceutical-grade medical cannabis products – including whole flower, oils and capsules – to tens of thousands of patients, physicians, pharmacies, hospitals, governments and researchers around the world for commercial, compassionate access and research purposes. In 2017, the company is focused on expanding global distribution of its products to additional countries in Europe and Latin America.
